Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endogenous retrovirus group S71 member 1 envelope protein (ERVS71-1 (also found as ENVT1 in some databases))
- Target
- ERVS71-1 (also found as ENVT1 in some databases)
- Molecular classification
- Retroviral envelope protein, Viral-derived protein, Other
01
Overview
Endogenous retrovirus group S71 member 1 envelope protein (ERVS71-1, also known as ENVT1) is a human protein encoded by a genetic locus derived from ancient viral integration into the germline. The protein is a member of the family of endogenous retroviral envelope proteins, which in their active viral forms can mediate receptor engagement and membrane fusion during early infection. In the case of ERVS71-1, the envelope protein is considered a "fossil" remnant, having lost its original fusogenic properties and lacking clear evidence of ongoing biological or pathogenic function in humans. While some endogenous retroviral envelopes are co-opted in mammals for specialized roles such as placental development and immune modulation, this particular member has not been characterized as therapeutically relevant, nor is it an established biomarker or a target for any pharmaceutical intervention.
- Other names
- ENVT1GC00U933623GC19P022367endogenous retrovirus group S71, member 119p13.11
02
Mechanism of action
Not applicable (no drugs known to interact or modulate this envelope protein in a therapeutic context)
03
Biological functions
May have *structural molecule activity* as annotated in gene ontologyRelated viral envelope proteins (from endogenous retroviruses) can mediate receptor recognition and membrane fusion; however, this specific protein is described as having lost its original fusogenic propertiesIn related endogenous retroviral envelopes, proteins can contribute to placental development, immune modulation, or have immunosuppressive effects, but this precise variant is not known to do so
04
Disease associations
Other (no strong evidence for direct involvement in major human disease)Some endogenous retroviral envelope proteins have been implicated in placental function, immune function, and occasionally in cancer or autoimmunity, but there is no direct indication of a disease role for this specific protein
05
Safety considerations
None known or reported for this molecule as a targetEndogenous retroviral proteins as a group have theoretical risks if overexpressed, but this specific envelope variant is not associated with safety signals
06
Interacting drugs
None known
07
Biomarkers
None established (ERV envelope proteins in general are being studied as biomarkers in some contexts, but not ERVS71-1 specifically)
Beyond the preview
Go deeper on Endogenous retrovirus group S71 member 1 envelope protein (ERVS71-1 (also found as ENVT1 in some databases)).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endogenous retrovirus group S71 member 1 envelope protein (ERVS71-1 (also found as ENVT1 in some databases)).